4/21
02:07 pm
glue
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise [Yahoo! Finance]
Low
Report
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise [Yahoo! Finance]
4/21
01:59 pm
glue
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise [Globe and Mail, The (Toronto, Canada)]
Low
Report
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise [Globe and Mail, The (Toronto, Canada)]
4/20
07:00 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Low
Report
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
3/21
08:18 pm
glue
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story [Yahoo! Finance]
Medium
Report
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story [Yahoo! Finance]
3/21
01:31 am
glue
Medium
Report
3/18
09:17 am
glue
Monte Rosa Therapeutics (GLUE) had its price target lowered by Guggenheim from $34.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Monte Rosa Therapeutics (GLUE) had its price target lowered by Guggenheim from $34.00 to $30.00. They now have a "buy" rating on the stock.
3/18
09:17 am
glue
Monte Rosa Therapeutics (GLUE) had its price target lowered by Wells Fargo & Company from $30.00 to $29.00. They now have an "overweight" rating on the stock.
Low
Report
Monte Rosa Therapeutics (GLUE) had its price target lowered by Wells Fargo & Company from $30.00 to $29.00. They now have an "overweight" rating on the stock.
3/18
05:17 am
glue
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
3/17
08:51 am
glue
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans [Yahoo! Finance]
3/17
07:37 am
glue
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
3/17
07:00 am
glue
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Low
Report
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
3/16
07:08 am
glue
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]
3/16
07:00 am
glue
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Low
Report
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
3/8
12:42 am
glue
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering [Yahoo! Finance]
Low
Report
Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering [Yahoo! Finance]
3/7
09:23 pm
glue
How Monte Rosa's MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE's Risk-Reward Profile [Yahoo! Finance]
Low
Report
How Monte Rosa's MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE's Risk-Reward Profile [Yahoo! Finance]
2/24
07:00 am
glue
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Low
Report
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
2/23
07:22 am
glue
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/23
07:00 am
glue
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
2/6
10:46 am
glue
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains [Yahoo! Finance]
2/6
06:31 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.